Propranolol as an alternative treatment option for pediatric lymphatic malformation

Michio Ozeki, Kaori Kanda, Norio Kawamoto, Hidenori Ohnishi, Akihiro Fujino, Masahiro Hirayama, Zenichiro Kato, Eiichi Azuma, Toshiyuki Fukao, Naomi Kondo

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Lymphatic malformation (LM), which was previously termed lymphangioma, is a rare congenital malformation of the lymphatic system and its treatment is still challenging. Propranolol (beta blocker) has been recently developed as a first-line treatment of infantile hemangioma. Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D). Six Japanese patients with LM (age range: 10 months-19 years old; 2 macrocystic, 2 microcystic and 2 combined type) were enrolled. Oral propranolol was administered at 2 mg/kg/day. The efficacy of propranolol for LM was evaluated by the rate of volume change as calculated from MRI imaging and by symptomatic improvement. In all patients, there were no significant side effects. Patients 3 and 5 were classified as objective responders with tumor volume reduction of 30.6% and 22.9%, respectively, at 24 weeks. Patient 1 showed 8% tumor volume reduction and patient 6 showed symptomatic improvement, hence, both were classified as minimal responders. The other two patients were classified as non-responders. Plasma VEGF-A, C, and D levels were significantly higher in the LM group than in the controls (all P < 0.01 by Mann-Whitney test). VEGF-A and D levels at 24 weeks were significantly lower than those at pre-treatment (P = 0.031, 0.047 by Wilcoxon matched pairs test). Though further trials with this treatment must be carried out, we propose that propranolol may be an alternative therapy option for intractable LM.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalTohoku Journal of Experimental Medicine
Volume229
Issue number1
DOIs
Publication statusPublished - 2012 Dec 21

Fingerprint

Pediatrics
Propranolol
Vascular Endothelial Growth Factor D
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor C
Tumors
Tumor Burden
Therapeutics
Lymphangioma
Lymphatic System
Magnetic resonance imaging
Hemangioma
Complementary Therapies
Plasmas
Imaging techniques
Control Groups

Keywords

  • Beta blocker
  • Lymphangioma
  • Lymphatic malformation
  • Propranolol
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ozeki, M., Kanda, K., Kawamoto, N., Ohnishi, H., Fujino, A., Hirayama, M., ... Kondo, N. (2012). Propranolol as an alternative treatment option for pediatric lymphatic malformation. Tohoku Journal of Experimental Medicine, 229(1), 61-66. https://doi.org/10.1620/tjem.229.61

Propranolol as an alternative treatment option for pediatric lymphatic malformation. / Ozeki, Michio; Kanda, Kaori; Kawamoto, Norio; Ohnishi, Hidenori; Fujino, Akihiro; Hirayama, Masahiro; Kato, Zenichiro; Azuma, Eiichi; Fukao, Toshiyuki; Kondo, Naomi.

In: Tohoku Journal of Experimental Medicine, Vol. 229, No. 1, 21.12.2012, p. 61-66.

Research output: Contribution to journalArticle

Ozeki, M, Kanda, K, Kawamoto, N, Ohnishi, H, Fujino, A, Hirayama, M, Kato, Z, Azuma, E, Fukao, T & Kondo, N 2012, 'Propranolol as an alternative treatment option for pediatric lymphatic malformation', Tohoku Journal of Experimental Medicine, vol. 229, no. 1, pp. 61-66. https://doi.org/10.1620/tjem.229.61
Ozeki, Michio ; Kanda, Kaori ; Kawamoto, Norio ; Ohnishi, Hidenori ; Fujino, Akihiro ; Hirayama, Masahiro ; Kato, Zenichiro ; Azuma, Eiichi ; Fukao, Toshiyuki ; Kondo, Naomi. / Propranolol as an alternative treatment option for pediatric lymphatic malformation. In: Tohoku Journal of Experimental Medicine. 2012 ; Vol. 229, No. 1. pp. 61-66.
@article{e29c4eec79dc4e2da3926367ee2cd8a5,
title = "Propranolol as an alternative treatment option for pediatric lymphatic malformation",
abstract = "Lymphatic malformation (LM), which was previously termed lymphangioma, is a rare congenital malformation of the lymphatic system and its treatment is still challenging. Propranolol (beta blocker) has been recently developed as a first-line treatment of infantile hemangioma. Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D). Six Japanese patients with LM (age range: 10 months-19 years old; 2 macrocystic, 2 microcystic and 2 combined type) were enrolled. Oral propranolol was administered at 2 mg/kg/day. The efficacy of propranolol for LM was evaluated by the rate of volume change as calculated from MRI imaging and by symptomatic improvement. In all patients, there were no significant side effects. Patients 3 and 5 were classified as objective responders with tumor volume reduction of 30.6{\%} and 22.9{\%}, respectively, at 24 weeks. Patient 1 showed 8{\%} tumor volume reduction and patient 6 showed symptomatic improvement, hence, both were classified as minimal responders. The other two patients were classified as non-responders. Plasma VEGF-A, C, and D levels were significantly higher in the LM group than in the controls (all P < 0.01 by Mann-Whitney test). VEGF-A and D levels at 24 weeks were significantly lower than those at pre-treatment (P = 0.031, 0.047 by Wilcoxon matched pairs test). Though further trials with this treatment must be carried out, we propose that propranolol may be an alternative therapy option for intractable LM.",
keywords = "Beta blocker, Lymphangioma, Lymphatic malformation, Propranolol, Vascular endothelial growth factor",
author = "Michio Ozeki and Kaori Kanda and Norio Kawamoto and Hidenori Ohnishi and Akihiro Fujino and Masahiro Hirayama and Zenichiro Kato and Eiichi Azuma and Toshiyuki Fukao and Naomi Kondo",
year = "2012",
month = "12",
day = "21",
doi = "10.1620/tjem.229.61",
language = "English",
volume = "229",
pages = "61--66",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "1",

}

TY - JOUR

T1 - Propranolol as an alternative treatment option for pediatric lymphatic malformation

AU - Ozeki, Michio

AU - Kanda, Kaori

AU - Kawamoto, Norio

AU - Ohnishi, Hidenori

AU - Fujino, Akihiro

AU - Hirayama, Masahiro

AU - Kato, Zenichiro

AU - Azuma, Eiichi

AU - Fukao, Toshiyuki

AU - Kondo, Naomi

PY - 2012/12/21

Y1 - 2012/12/21

N2 - Lymphatic malformation (LM), which was previously termed lymphangioma, is a rare congenital malformation of the lymphatic system and its treatment is still challenging. Propranolol (beta blocker) has been recently developed as a first-line treatment of infantile hemangioma. Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D). Six Japanese patients with LM (age range: 10 months-19 years old; 2 macrocystic, 2 microcystic and 2 combined type) were enrolled. Oral propranolol was administered at 2 mg/kg/day. The efficacy of propranolol for LM was evaluated by the rate of volume change as calculated from MRI imaging and by symptomatic improvement. In all patients, there were no significant side effects. Patients 3 and 5 were classified as objective responders with tumor volume reduction of 30.6% and 22.9%, respectively, at 24 weeks. Patient 1 showed 8% tumor volume reduction and patient 6 showed symptomatic improvement, hence, both were classified as minimal responders. The other two patients were classified as non-responders. Plasma VEGF-A, C, and D levels were significantly higher in the LM group than in the controls (all P < 0.01 by Mann-Whitney test). VEGF-A and D levels at 24 weeks were significantly lower than those at pre-treatment (P = 0.031, 0.047 by Wilcoxon matched pairs test). Though further trials with this treatment must be carried out, we propose that propranolol may be an alternative therapy option for intractable LM.

AB - Lymphatic malformation (LM), which was previously termed lymphangioma, is a rare congenital malformation of the lymphatic system and its treatment is still challenging. Propranolol (beta blocker) has been recently developed as a first-line treatment of infantile hemangioma. Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D). Six Japanese patients with LM (age range: 10 months-19 years old; 2 macrocystic, 2 microcystic and 2 combined type) were enrolled. Oral propranolol was administered at 2 mg/kg/day. The efficacy of propranolol for LM was evaluated by the rate of volume change as calculated from MRI imaging and by symptomatic improvement. In all patients, there were no significant side effects. Patients 3 and 5 were classified as objective responders with tumor volume reduction of 30.6% and 22.9%, respectively, at 24 weeks. Patient 1 showed 8% tumor volume reduction and patient 6 showed symptomatic improvement, hence, both were classified as minimal responders. The other two patients were classified as non-responders. Plasma VEGF-A, C, and D levels were significantly higher in the LM group than in the controls (all P < 0.01 by Mann-Whitney test). VEGF-A and D levels at 24 weeks were significantly lower than those at pre-treatment (P = 0.031, 0.047 by Wilcoxon matched pairs test). Though further trials with this treatment must be carried out, we propose that propranolol may be an alternative therapy option for intractable LM.

KW - Beta blocker

KW - Lymphangioma

KW - Lymphatic malformation

KW - Propranolol

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84873055186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873055186&partnerID=8YFLogxK

U2 - 10.1620/tjem.229.61

DO - 10.1620/tjem.229.61

M3 - Article

C2 - 23257321

AN - SCOPUS:84873055186

VL - 229

SP - 61

EP - 66

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 1

ER -